We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Sysmex and Siemens Extend Partnership in Hemostasis Testing

By LabMedica International staff writers
Posted on 26 May 2016
Sysmex Corporation (Kobe, Japan) and Siemens Healthcare Laboratory Diagnostics (NY, USA) have announced an extension to their long-standing partnership through at least 2020. More...
The contract extension adds a minimum of two additional years to the global supply, distributorship, and sales and service agreement for hemostasis clinical testing products.

The partnership enables clinical laboratories around the world to continue to benefit from the large portfolio. The companies, which began collaborating over 20 years ago, also agreed to continue joint hemostasis product development activities that will streamline and optimize lab testing.

Siemens Healthcare and Sysmex provide products used to test for blood clotting disorders, preoperative bleeding risk management, and monitoring of patients on anticoagulant therapy medications. In the past few years alone, the companies have introduced several cutting-edge INNOVANCE reagents and multiple new platforms for various laboratory settings, including the recent worldwide launch of the Sysmex CS-2500 System, and the US launch of the Sysmex CS-5100 System with optional track-based automation. (The products are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed.)

The relationship extension was celebrated in April 2016 at Siemens AG headquarters in Munich (Germany). “We are pleased to extend our longstanding partnership with Siemens Healthcare,” said Hisashi Ietsugu, Chairman and CEO, Sysmex Corporation, “With the aging population, hemostasis testing has become even more important. Our partnership provides our customers with the innovative technologies needed to manage the increase in testing volumes, while providing accurate results for improved patient care.”

“The continued collaboration and 20-year partnership between Siemens and Sysmex is rare in the rapidly changing world of diagnostics,” said Franz Walt, President, Siemens Healthcare Laboratory Diagnostics, “As a leader in hemostasis testing, our combined mission to offer best-in-class solutions has enabled us to meet the needs of diverse laboratories throughout the world.”

Related Links:
Sysmex
Siemens Healthcare Laboratory Diagnostics

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.